We are developing AI capabilities to help find actionable markers to identify potential therapeutic and clinical trial options for your patients.Contact Us
Our developing portfolio of digital pathology algorithms use a single whole slide H&E image to predict biomarkers, such as MSI or HRD status, for patients who are not ordinarily sequenced.
Our algorithms are being developed to use an H&E whole slide image to identify patients likely to contain characteristics relevant for clinical trial eligibility through our unique biomarker prediction technology.
We can serve as a partner to your practice in digitizing your pathology workflow, from scanning to integrating algorithms into your existing workflow to uncover more potential options for patients.
of data, which represent 14 times the size of the Cancer Genome Atlas
oncologists rely on Tempus as their precision medicine partner
of all Academic Medical Centers in the US are connected to Tempus
MET is a proto-oncogene whose somatic activation in non-small cell lung cancer leads to increased cell growth and tumor progressionRead abstract
Deep Learning Identifies Microsatellite Instability in H&E Whole Slide Images from Prostate, Esophageal, and Gastric Cancers and Generalizes across Cancer TypesRead abstract
Effects of Color Calibration via ICC Profile on Inter-scanner Generalization of AI ModelsRead abstract
AI-augmented histopathologic review using SmartPath could decrease tissue waste, sequencing time, and laboratory costs by optimizing DNA yields and tumor purityRead abstract
Deep Orthogonal Fusion: Multimodal Prognostic Biomarker Discovery Integrating Radiology, Pathology, Genomic, and Clinical DataRead abstract
We believe that AI solutions can open the door to more treatment options for patients by identifying actionable markers leading to potential novel therapies and clinical trials.
Thank you for your inquiry, we have sent an email to you with more information.